Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | EYA2 | O00167 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL562965 | 0.73 | TDP1 (0.47) | TDP1EYA2APPACETSHR | |
| SCHEMBL6792984 | 0.73 | TDP1 (0.47) | TDP1EYA2APPACETSHR | |
| SCHEMBL2687920 | 0.69 | TDP1 (0.43) | TDP1EYA2APPACETSHR | |
| SCHEMBL10002665 | 0.69 | TDP1 (0.43) | TDP1EYA2APPACETSHR | |
| SCHEMBL10002664 | 0.69 | TDP1 (0.43) | TDP1EYA2APPACETSHR | |
| SCHEMBL7718304 | 0.69 | TDP1 (0.43) | TDP1EYA2APPACETSHR | |
| SCHEMBL4689987 | 0.69 | TDP1 (0.43) | TDP1EYA2APPACETSHR | |
| SCHEMBL28008151 | 0.69 | TDP1 (0.43) | TDP1EYA2APPACETSHR | |
| SCHEMBL7055782 | 0.67 | — | — | |
| SCHEMBL21778 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293660-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-11-27 | — | — | US | disclosed |
| US-7351855-B2 | Chemically defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070254851-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | LA JOLLA PHARMACEUTICAL COMPANY | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293660-A1 | CHEMICALLY-DEFINED NON-POLYMERIC VALENCY PLATFORM MOLECULES AND CONJUGATES THEREOF | SSB, PCNA, NCL | TDP1 398/4885EYA2 3645/4885APP 3782/4885 |
| US-20070254851-A1 | Chemically-defined non-polymeric valency platform molecules and conjugates thereof | SSB, PCNA, NCL | TDP1 398/4885EYA2 3645/4885APP 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.